Johnson & Johnson shares dip amid rising selling pressure

Traders Union
All News
Financial News
Johnson & johnson slides 2.24% today

Highlights

Godfrey Financial Associates Inc. initiated a $940,000 position in Johnson & Johnson in Q4, signaling new institutional interest.
Inspire Trust Co. N.A. trimmed its stake by 13.9%, indicating some institutional profit-taking amid broader selling pressure.
Johnson & Johnson faces near-term technical resistance with mixed momentum signals, but four weekly indicators support an upward move toward $226.77.

Institutional repositioning continues despite sustained selling trend

Godfrey Financial Associates Inc. acquired a new position in Johnson & Johnson during the fourth quarter, purchasing 4,541 shares valued at approximately $940,000. At the same time, Inspire Trust Co. N.A. reduced its holdings in the company by 13.9%, selling 5,000 shares and holding 31,000 shares after the transaction. These portfolio adjustments by institutional investors were reported, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, points out that Johnson & Johnson remains under clear short- and medium-term selling pressure. He notes that the recent decline below both 20- and 50-day moving averages signals persistent technical weakness. Institutional flows are mixed, as some funds have cut their positions, reflecting low confidence despite long-term support above the 200-day average. Kharitonov also stresses the overbought signals in some momentum indicators and cautions that the stock may be vulnerable if support at $222.10 breaks. "The setup currently favors sellers, and unless buying strength returns above $227.79, downside risk should not be underestimated," he says.

Viktoras Karapetjanc, expert at Traders Union, sees resilience in Johnson & Johnson's overall bullish structure, despite the short-term dip. He highlights that strong institutional interest and robust long-term indicators maintain upside potential. Karapetjanc believes that with the stock holding well above the 200-day moving average, further growth is likely if resistance at $227.79 is cleared. "The market offers attractive setups for buyers as momentum builds, and further upside can be expected once short-term pressure fades," he comments.

Mixed momentum and support test as price approaches session low

Johnson & Johnson is currently trading below both its 20-day ($227.79) and 50-day ($232.77) moving averages, but remains well above its long-term 200-day moving average at $211.62. This setup implies short- and medium-term pressure from sellers, despite longer-term upward structure; the next dynamic support is near the Ichimoku Kijun level at $227.72, and resistance stands at the 50-day moving average. Momentum indicators are mixed: the MACD and Average Directional Index (ADX) on the daily chart are both neutral, highlighting a lack of strong directional conviction. The Relative Strength Index (RSI) reads 51.76 (mildly bullish), but both the Stochastic RSI and Commodity Channel Index (CCI) point to neutral and overbought levels, respectively. Bull/Bear Power (BBP) is significantly positive at 2.01, indicating buyers remain dominant; however, the overbought reading suggests the advance may be stretched. Awesome Oscillator supports a bullish tone, but the daily movement shows the stock down $5.18 or 2.24% after a downside gap of $2.64, with price now near the session low. Intraday volatility stands at 1.30%, confirming pressure after the open as the stock tests support.

Earlier, analysts noted that Johnson & Johnson maintained a constructive outlook, supported by long-term bullish structure despite medium-term resistance. The current action, marked by intensified selling pressure against a backdrop of mixed momentum signals, highlights the importance of monitoring the $227.79 resistance and $222.10 support as key catalysts for the next directional move.

Source of Data: JNJ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.